SOURCE-LINKED STUDY SUMMARY
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- NOPARK tested whether a NAD precursor improved early Parkinson disease outcomes.
- Who / model studied
- 410 randomized participants; 393 in the primary analysis.
- Studied dose & schedule
- Oral nicotinamide riboside 500 mg twice daily versus placebo for 52 weeks, alongside stable dopaminergic treatment.
- What the study found
- The primary symptom score favored placebo: adjusted difference 2.72 points (95% CI 0.47–4.98), indicating greater worsening with NR. Four key secondary outcomes were null. Serious adverse events: 8.3% versus 14.1%.
- Limitations & context
- Statistical worsening does not automatically mean a large clinical effect; adverse-event imbalance does not prove safety superiority. Disease-specific findings do not settle healthy-user or other NAD interventions. Abstract assessment.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2026.18828